It was shown that that co-inhibitory immune checkpoint blockade (e.g., anti-PD-1, anti-CTLA-4) reduced glucose uptake by the tumor cells reinstating glucose availability for the T cells. This evidence concerns the gene PDCD1 and neoplasm.